The clinical and pharmacokinetic profile as well as the p217+tau biomarker response observed in these Phase 1 trials are favorable and support further study of JNJ-63733657 to determine if this antibody is able to slow tau spread and the clinical course of AD. This evidence concerns the gene MAPT and Alzheimer disease.